Australian medical technology firm 4DMedical has announced a significant dual achievement, securing CE Mark certification for its CT:VQ™ imaging software in the European Union. This regulatory approval coincides with the successful raising of US$57 million through a private placement with institutional investors. The new capital is designated to support the company's growth initiatives, primarily the commercial launch of its innovative technology across Europe.
A New Frontier in Lung Imaging
CT:VQ™ represents a major advancement in respiratory diagnostics as the world's first non-contrast ventilation-perfusion imaging technology. It provides quantitative insights into functional lung health using data from routine non-contrast CT scans. This process uniquely eliminates the need for radiotracers and specialized nuclear medicine infrastructure, streamlining the diagnostic workflow for clinicians.
The technology addresses a critical gap in pulmonary medicine, where disease is functional but imaging has traditionally been structural. By generating detailed ventilation and perfusion maps, CT:VQ™ allows clinicians to visualize regional lung function with the anatomical clarity of a CT scan. This integration provides a more comprehensive understanding of a patient's respiratory condition within existing hospital workflows.
Strategic Entry into the European Market
Receiving the CE Mark opens access to one of the world's largest and most sophisticated healthcare markets for 4DMedical. This certification, combined with its existing FDA clearance in the United States, allows for rapid commercialization across two major global regions. The company is now poised to introduce its technology to the European Union's population of more than 450 million people.
The European market presents a substantial opportunity, with a highly developed hospital imaging infrastructure and an extensive installed base of CT scanners. An estimated 400,000 nuclear VQ scans are performed annually across the EU, highlighting the significant clinical need for an improved solution. CT:VQ™ is designed to overcome the common constraints of conventional nuclear imaging, including radiotracer availability and operational complexity.
Financial Backing and U.S. Momentum
The concurrent $57 million private placement provides the necessary capital to execute the company's ambitious expansion plans. These funds will directly support the commercial rollout of CT:VQ™ in Europe and other key growth strategies. This financial backing underscores investor confidence in the technology's potential to transform cardiothoracic imaging on a global scale.
4DMedical's European strategy is bolstered by its growing momentum in the United States, where the technology is already deployed at six leading academic medical centers. Institutions such as Stanford, Cleveland Clinic, and the Mayo Clinic have adopted the software. This successful U.S. adoption provides a proven blueprint for engaging with leading European hospitals and clinical teams.
Future Outlook and Company Vision
Andreas Fouras, CEO and Founder of 4DMedical, stated that the clinical need for CT:VQ™ is universal, as the limitations of nuclear scanning are a global problem. He highlighted that Europe's clinical expertise and research leadership will be instrumental in the technology's adoption and evidence generation. The company is now advancing plans for widespread commercial engagement across the continent.
The company will focus on working with leading hospitals and clinicians on adoption, evaluation, and research initiatives for its software. The goal is to seamlessly integrate CT:VQ™ into existing clinical workflows to enhance diagnostic accuracy and operational efficiency. This patient-specific information is designed to support better decision-making for a range of respiratory conditions.
The combination of regulatory approval in a major new market and substantial new funding marks a pivotal moment for 4DMedical. By providing a more accessible and efficient alternative to traditional lung function imaging, CT:VQ™ is positioned to make a significant impact on patient care. The company's strategic expansion into Europe, built on a foundation of success in the U.S., signals a new era for cardiothoracic diagnostics.